Custom zinc finger nucleases (ZFNs) ^[@R7]--[@R9]^ and TALENs^[@R1]--[@R5]^ have been used introduce locus-specific double-stranded breaks in the zebrafish genome, generating dozens of mutant alleles^[@R10]^. Recent work has been facilitated by the relatively straightforward DNA base recognition cipher underlying TALEN technology^[@R11],[@R12]^. However, the efficacy of previously described custom sequence-specific nucleases was limiting in some applications^[@R1]--[@R5],[@R7]--[@R9]^. For example, standard TALENs using the pTAL scaffold^[@R13]^ ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) targeting exon 2 of the zebrafish *ponzr1* locus^[@R14]^ resulted in a measurable level of locus modification in somatic tissue (median value of 5%; [Fig. 1b--c](#F1){ref-type="fig"}). This pTAL-*ponzr1* pair yielded 4 germline-transmitting founder animals carrying a mutation in *ponzr1* out of the 24 tested ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). TALENs against a second locus (*crhr1*) using the pTAL scaffold yielded a modest rate of locus modification (\<1%; [Fig. 1b--c](#F1){ref-type="fig"}). These results are characteristic of the standard TALEN efficacy range demonstrating room for improvement.

Multiple TALEN scaffold designs have been described^[@R13],[@R15],[@R16]^, including those with different N- and C-terminal truncations, diverse FokI nuclease linkers, and various nuclear localization sequences. To improve *in vivo* efficacy, we tested the GoldyTALEN scaffold ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}; [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) in an mRNA expression vector backbone (pT3TS^[@R17]^) using DNA analysis that measures the loss of a restriction enzyme recognition sequence at the TALEN cut site ([Fig. 1a](#F1){ref-type="fig"}). Using the same recognition domains in the GoldyTALEN scaffold, there is a 6-fold increase in somatic gene modification at the *ponzr1* locus ([Fig. 1b--c](#F1){ref-type="fig"}; [Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}) over the pTAL scaffold. The germline modification rate was similarly increased when switching scaffolds, from 17% (4/24; pTAL-*ponzr1*; [Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}) to 71% (10/14; GoldyTALEN-*ponzr1*; [Supplementary Fig. 3e](#SD1){ref-type="supplementary-material"}). We also detected improved efficacy using a cell-free assay system with *in vitro* translated TALEN protein and purified *ponzr1* PCR DNA ([Fig. 1d](#F1){ref-type="fig"}). The GoldyTALENs against *crhr1* showed an increase in the genome modification rate, improving from \<1% to 7% median cutting efficacy ([Fig. 1b--c](#F1){ref-type="fig"}; [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Sequence comparisons of pTAL and GoldyTALEN scaffolds in both loci demonstrate similar indels at the cut site, which is diagnostic of NHEJ repair ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}).

To further test the efficacy of the GoldyTALEN scaffold, we generated TALENs against three additional loci (*moesina*, *ppp1cabb* and *cdh5*; [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). We observed efficient gene modification at each locus (5 out of 5 loci total; [Fig. 1](#F1){ref-type="fig"} and [Fig. 2a](#F2){ref-type="fig"}). In three instances, the mutagenesis efficiency ranged from 70 to 100% as demonstrated by loss of the restriction enzyme recognition sequence at the TALEN cut sites ([Fig. 2a](#F2){ref-type="fig"}) and DNA sequence analyses ([Supplementary Fig. 4b--d](#SD1){ref-type="supplementary-material"}) of amplicons from pooled injected embryos. To determine the time-course of the GoldyTALEN-induced changes, we examined restriction enzyme nuclease activity at 256-cell, 28 hours post fertilization (hpf) and 50 hpf stages. A majority of the DNA was modified by the 256-cell stage ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). Together, these results indicate early, efficient gene targeting in somatic tissues including biallelic conversion in some animals. Somatic targeting efficacy using the GoldyTALEN scaffold compares favorably with previous TALEN scaffolds in zebrafish, with 3 of 5 GoldyTALENs demonstrating as high or higher mutation frequency as any of the previously reported loci using the first generation TALEN systems^[@R1]--[@R5]^.

In response to the increased efficacy of the GoldyTALENs, we asked whether injection of TALENs could recapitulate a known MO^[@R6]^ loss of function phenotype. We conducted a dose-response curve of the *moesina*, *ppp1cab* and *cdh5* GoldyTALEN pairs, optimizing GoldyTALEN concentration to the number of embryos with biallelic changes, and percent dead or malformed embryos ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). Embryos injected with either *cdh5* GoldyTALENs ([Fig. 2d](#F2){ref-type="fig"}) or MOs^[@R18]^ ([Fig. 2c](#F2){ref-type="fig"}) displayed similar vascular phenotypes: pronounced cardiac edema ([Fig. 2b](#F2){ref-type="fig"}, top panels), loss of patent lumens in the Tg(*fli1-egfp*)^y1^ vasculature^[@R19]^ ([Fig. 2c, d](#F2){ref-type="fig"}, bottom panels), and loss of circulating Tg(*gata1:dsred*)^sd2^ red blood cells^[@R20]^ ([Fig. 2c, d](#F2){ref-type="fig"}, bottom panels; [Supplementary Movies 1--3](#SD1){ref-type="supplementary-material"}). A similar pericardial edema phenotype was observed in F1 offspring from F0 *cdh5* founder incrosses (data not shown), suggesting specificity of the phenotype described in F0s to *cdh5* loss of function. Furthermore, *cdh5* GoldyTALEN-injected embryos display little or no Cdh5 protein ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). Together, these results indicate that the GoldyTALEN platform can achieve efficient biallelic targeting recapitulating known loss-of-function phenotypes. Furthermore, these data demonstrate that GoldyTALENs have the potential to be a complementary, but distinct, approach to MO-based somatic phenotype assessment.

The biallelic GoldyTALEN-injected fish were raised to assess germline mutation transmission. The *moesina*, *ppp1cab* or *cdh5* F0 founders were outcrossed. Ten pooled F1 embryos were screened and displayed a 9 to 55% locus mutation frequency ([Supplementary Fig. 8a--c](#SD1){ref-type="supplementary-material"}). From two founder F0 outcrosses per locus, 10 individual F1 embryos were sequenced with mutant alleles identified in 20% to 100% of the F1 offspring ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}). Furthermore, in two out of three of these loci we detected germline mosaicism, suggesting several independent repair events. These data indicate that the efficient somatic TALEN targeting is effectively passed through the germline.

Recent *in vitro* work demonstrates that ssDNA can be an effective donor for HDR-based genome editing at a ZFN-induced double-stranded break^[@R21],[@R22]^. With the highly efficient genome modification success of GoldyTALENs, we hypothesized that synthetic oligos designed to span the predicted TALEN cut site could serve as a template for HDR *in vivo* ([Fig. 3](#F3){ref-type="fig"}). Using *ponzr1* as a test locus, we introduced an *EcoRV* restriction site by co-injection of *ponzr1* GoldyTALENs and a ssDNA oligo ([Fig. 3a](#F3){ref-type="fig"}). In these experiments, 42 of 74 injected embryos displayed a detectable level of chromosomes containing the introduced *EcoRV* sequence with an estimated 9% ratio of converted chromosomes in these animals ([Supplementary Fig 9a](#SD1){ref-type="supplementary-material"}). Sequence analysis indicated two precisely modified chromosome events from different larvae ([Supplementary Fig. 9b](#SD1){ref-type="supplementary-material"}) demonstrating successful somatic HDR at the *ponzr1* locus. Other events show precise addition at the 3′ end while small indels were noted at the 5′ side of the modification site ([Supplementary Fig. 9c](#SD1){ref-type="supplementary-material"}). Several homology arm lengths were tested for the highest HDR signal. In this experimental approach, an increase in homology arm length that spanned the TALEN binding site decreased the frequency of HDR events ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

To test whether the HDR sequence modification was stably maintained in zebrafish somatic tissue, fin biopsies from two month-old fish were assayed for addition of the *EcoRV* sequence at the *ponzr1* locus. Out of 186 fish, 8 showed a visible incorporation of *EcoRV* ([Supplementary Fig. 9c](#SD1){ref-type="supplementary-material"}). To determine whether a lack of somatic *EcoRV* incorporation also indicated a lack of germline incorporation, 13 randomly selected fish with *EcoRV*-negative fin biopsies were outcrossed. The offspring from all 13 adults were negative for *EcoRV* incorporation at the *ponzr1* locus (clutch sizes ranged from 16--96 embryos). Therefore, fin biopsy positive fish were prioritized for determining germline transmission. Outcross embryos from three out of four fin tissue positive fish yielded clutches with introduction of the *EcoRV* site at the *ponzr1* locus ([Fig. 3b](#F3){ref-type="fig"}). Two out of three of these germline fish demonstrated precise EcoRV addition ([Fig. 3c](#F3){ref-type="fig"}).

We next asked whether TALEN/oligo co-injection could introduce larger sequences such as a loxP site, an essential step in making Cre-dependent conditional genetic alleles. We used TALENs against an intron in the *crhr2* gene and a ssDNA oligo were used to add a modified loxP^JTZ17^ (mloxP)^[@R23]^ site at this location ([Fig. 4a](#F4){ref-type="fig"}). PCR analysis demonstrates somatic introduction of the mloxP sequence at the *crhr2* TALEN cut site ([Supplementary Fig. 10a](#SD1){ref-type="supplementary-material"}). Sequence characterization confirmed integration of the mloxP site in 3 assayed somatic chromosomes ([Supplementary Fig. 10b](#SD1){ref-type="supplementary-material"}). A similar method was used to introduce an mloxP sequence at the *ponzr1* locus ([Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"}). Sequencing confirmed precise somatic addition at this locus ([Supplementary Fig. 11b--c](#SD1){ref-type="supplementary-material"}).

Maintenance of somatic mloxP-modified *crhr2* chromosomes by fin bioposy was used to identify germline transmission of the mloxP sequence. Positive chromosomes were detected by quantitative PCR in 20 of 53 animals ([Supplementary Fig. 10a](#SD1){ref-type="supplementary-material"}). Embryos were obtained from 16 of the somatic-positive fish as well as 42 fish that had not been pre-screened by PCR. Both groups transmitted HDR events through the germline ([Fig. 4b](#F4){ref-type="fig"}). However, no significant enrichment for likely germline transmitting animals was noted, perhaps due to the less stringent PCR assay than used for *ponzr1*. In total, 6 out of 58 injected animals transmitted mloxP-modified chromosomes through the germline at the *crhr2* locus ([Fig. 4b](#F4){ref-type="fig"}). Sequence confirmation of three of these fish demonstrated a precise HDR event as well as other, non-precise events ([Fig. 4c](#F4){ref-type="fig"}).

Here, we focused on local genome editing changes induced by TALENs, especially those induced by HDR. However, more complete analyses will be required to assess any, off-target effects of TALENs or ssDNA-based HDR. Whole genome sequencing on germline-transmitting fish from different parental lines would be particularly instructive. Should this analysis demonstrate off-target mutations, TALENs using obligate heterodimer-based nuclease fusions have recently been reported as an alternative approach^[@R3],[@R5],[@R24]^. Using obligate heterdimers in the GoldyTALEN scaffold is one future method for potentially optimizing HDR-directed gene editing specificity.

To our knowledge, these results represent the first description of successful HDR in zebrafish and the first demonstration of HDR using ssDNA as a donor template *in vivo*. This approach complements the error-prone NHEJ toolkit for model organisms ([Fig. 5](#F5){ref-type="fig"}). The use of ssDNA facilitates an array of genome changes, including the introduction of single nucleotide polymorphisms for vertebrate genetic applications. The asymmetry in precise editing suggests an additional mechanism for genome editing that incorporates both HDR and NHEJ ([Fig. 5](#F5){ref-type="fig"}). For example, the donor ssDNA may serve as a primer for new strand synthesis at the TALEN break. Extension from the 3′ end of the oligo would create long regions of homology for recombination. However, the 5′ end of the oligo limits the extent of strand invasion and a limited opportunity for HDR. This leads to 5′ end resolution by either HDR or NHEJ. For applications where new sequences are introduced into non-coding genomic regions, such as the introduction of loxP sites into intronic sequences, either event will likely be of high utility.

Using the zebrafish, we report an updated TALEN system for use in genome modification and functional genomic applications. The high efficacy enables new approaches, including somatic gene targeting for reverse genetics applications. Furthermore, we show that synthetic ssDNA oligos can be used with this TALEN system for genome editing including the precise introduction of exogenous DNA sequence at a specific locus. Although deployed here in zebrafish, this approach has the potential to be effective for *in vivo* applications in a wide array of model organisms.

Methods Summary {#S1}
===============

TALENs were assembled via the GoldenGate method^[@R13]^. For ease of analysis, TALENs recognition sequences flanked a unique restriction site within the targeted gene. TALEN RVDs were cloned into a pT3TS^[@R17]^-driven TALEN scaffold, and mRNA was injected into single-cell zebrafish embryos. The injected larvae were either molecularly tested or raised for germline mutation analysis. Somatic and germline TALEN-induced mutations were evaluated via PCR and restriction fragment length polymorphisms. To induce HDR events, singe-stranded DNA oligonucleotides with either an EcoRV or mloxP site were designed with short homology arms around a TALEN target site and were injected into one-cell zebrafish embryos. PCR analysis of modified loci was used to detect the resulting somatic and germline HDR events. Detailed methods can be found in the [Supplementary Information](#SD1){ref-type="supplementary-material"}.

Full Methods {#S2}
============

TALEN Design {#S3}
------------

The software developed by the Bogdanove laboratory (<https://boglab.plp.iastate.edu/node/add/talen>) was initially used to find candidate binding sites as described^[@R13]^. Three criteria were used for TALEN design. First, TALEN binding sites were selected that ranged from 15--25 bases in length. Second, the spacer length was initially selected to be 14 to 18 base pairs (bps), but subsequent GoldyTALEN designs were restricted to 15--16 bps. Additionally, when possible TALEN cut sequences were selected around a restriction enzyme centrally located within the spacer. To simplify the TALEN design process, a free, open access software (Mojo Hand) was created and made available online ([www.talendesign.org](www.talendesign.org)). Mojo Hand downloads sequence from NCBI and uses an exhaustive database of commercially available restriction enzymes to identify TALEN binding sites with a restriction enzyme site in the spacer region to simplify downstream analysis (Neff et al (unpublished)). Mojo Hand also features a BLAST interface that will search genomes for potential second site effects.

TALEN Binding Sites and Spacer Regions {#S4}
--------------------------------------

The *ponzr1* TALEN recognition sequences are: left TALEN 5′-GTGAGCACCCAGCGGACCTCCTCT-3′ and right TALEN 5′-ATCAGAACAACAGTCAGAGAT-3′. Between the two binding sites is an 18 bp spacer with a *BstN*I sequence (GGAA[CCTGG]{.ul}ACCACGGGC, *BstN*I underlined). The *crhr1* TALEN recognition sequences are: left TALEN 5′-TGCAACACTGAGCTCTGTAAACCT-3′ and right TALEN 5′-CTGCTGCCGACTGGACCCTGAGGT-3′. Between the two binding sites is a 15 bp spacer with a *BstU*I site (GTC[CGCG]{.ul}TGTGGCGA, *BstU*I underlined). The *moesina* TALEN recognition sequences are: left TALEN 5′-ACCCAGAAGACGTTT-3′ and right TALEN 5′-CTTTGAGTGGCCTCCT-3′. Between the two binding sites is a 15 bp spacer with an *Xmn*I site (CTGAG[GAACTGATTC]{.ul}, *Xmn*I underlined). The *ppp1cab* TALEN recognition sequences are: left TALEN 5′-CCACCAGAGAGTAACT-3′ and right TALEN 5′-GCCTCTGTCAACATAGT-3′. Between the two binding sites is a 15 bp spacer with a *Bs*II site (A[CCTATTTCTGG]{.ul}GAG, *Bs*II underlined). The *cdh5* TALEN recognition sequences are: left TALEN 5′-CTCCTCAACATACATACT-3′ and right TALEN 5′-ACAAATGATTCATCTT-3′. Between the two binding sites is a 16 bp spacer with a *Hinc*II site (GGAGAGTTA[GTTGAC]{.ul}A, *Hinc*II underlined). The *crhr2* binding sites are: left TALEN 5′-GTCAAATCTGCAGCTCCACGCTT-3′ and right TALEN 5′-CCTCTGCCTCTGACTCTGT-3′. Between the two binding sites is a 15 bp spacer (CACGCCTCAGCAAAC).

TALEN Constructs {#S5}
----------------

TALEN assembly of the RVD-containing repeats was conducted using the Golden Gate approach^[@R13]^. Once assembled, the RVDs were cloned into a pT3TS destination vector with the appropriate TALEN backbone to generate mRNA expression plasmids -- pT3TS-TAL (pTAL) and pT3TS-GoldyTALEN (GoldyTALEN). *In vitro* transcription of TALEN mRNA was conducted by linearizing the expression plasmids with *Sac*I endonuclease at 37°C for 2--3 hours, transcribing the linearized DNA (T3 mMessage Machine kit, Ambion) and purifying the mRNA by phenol/chloroform extraction (T3 mMessage Machine kit user manual protocol) for injection.

TALEN Mutation Screening {#S6}
------------------------

One-cell embryos were microinjected with 50--400 pg of TALEN mRNA. The dose of each pair of TALENs injected was empirically determined, with up to a 3-fold difference noted between different TALEN pairs. In each case, conditions were used where over 50% embryos survived post-injection. Genomic DNA for [Figures 1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"} were collected at 2--4 dpf from 24--32 individual larvae by incubating in 50mM NaOH at 95°C, followed by cooling to 4°C and adding 1/10 volume 1M Tris-HCL pH 8.0^[@R25]^. Genomic DNA for [Figure 2](#F2){ref-type="fig"} was isolated from groups of 10 larval zebrafish using DNAeasy Blood and Tissue kit (Qiagen). Genotyping was conducted using PCR followed by restriction enzyme digest. For *ponzr1*, the primers were 5′-GTTCACACAAAATGTCTCTCAAGTCTCTAAATC -3′ and 5′-AGTGGCCAGTGAGTGTATGTTACCT -3′. For *crhr1* the primers were 5′-CGTGAAAGAGACAGCGAAGGGATTG -3′ and 5′-AGAAACTACCATTGTCACACTGAGCGAAG -3′. The primers for *moesina* were 5′-GTTACGGCTCAAGACGTC-3′ and 5′-CAGGATGCCCTCTTTAAC-3′. The primers for *ppp1cab* were 5′-GATGTTCATGGTCAGTAC-3′ and 5′-TGATTGAGGCACATTCATGG-3′. The primers for *cdh5* were 5′-TTGTTGTCCTTGCAAAGCTG-3′ and 5′-TCTAGAGGATTCGCTGAT-3′. The primers for *crhr2* were 5′-CCCTGATTGTGGAACTTTTCAGAACGTA-3′ and 5′-TGGTTTGGAATTAGTGCAGCATGAGTA-3′. Mutations were assessed by loss of restriction enzyme digestion. To sequence-verify mutations, the gel-purified, uncut PCR products were cloned into the TOPO® TA Cloning^®^ Kit (Invitrogen).

Analysis of cdh5 {#S7}
----------------

A *cdh5* morpholino^[@R18]^ was injected at the 1--4 cell stage into Tg(*fli1:efgp*)^y1^ embryos^[@R19]^. The vascular phenotype of the MO and the GoldyTALEN-injected embryos were assessed using a confocal microscope. Antibody staining using the cdh5 antibody^[@R26]^ was performed as described^[@R18]^.

Genome Editing {#S8}
--------------

For the *ponzr1* locus, a ssDNA oligo was designed to target the spacer sequence between the TALEN cut sites. The oligo extends to half the length of the TALEN recognition site. An *EcoR*V site (5′-GATATC-3′) or a modified loxP (mloxP) site (5′-ATAACTTCGTATAGCATACATTATAGCAATTTAT-3′) was introduced near the center of the oligo resulting in a 20-base homology arm on the 5′ end and an 18-base homology arm on the 3′ end. For the *crhr2* locus, the *crhr2* mloxP oligo (5′ --TCAAATCTGCAGCTCCACGCTTCACGCATAACTTCGTATAGCATACATTATAGCAAT TTATGCATATCTCCTTTTCTCGAAAAGTAAG -- 3′) was designed to replace the 3′ TALEN binding site with an mloxP site while providing 27 bases of homology at both 5′ and 3′ end. The oligos were ordered from Integrated DNA Technologies (IDT) and purified using the Nucleotide Removal Kit (Qiagen).

One-cell embryos were microinjected with both the GoldyTALEN mRNA and ssDNA donor. The ssDNA oligo dose was varied to improve the rate of HDR without impacting toxicity beyond 50% embryonic death post injection. For the *ponzr1* locus, 50--75 pg of *ponzr1* GoldyTALEN mRNA and 50--75 pg of the ssDNA donor. For the *crhr2* locus, 50 pg of *crhr2* GoldyTALEN mRNA was injected with either 25 pg or 50 pg of *crhr2* mloxP oligo. Genomic DNA was isolated as described above. If the embryos were injected with the *EcoR*V oligo, PCR was conducted using the same primers as listed above and the product was digested using *EcoRV*. The full-length amplicon from *EcoRV*-positive larvae was cloned into a TOPO® TA Cloning^®^ Kit (Invitrogen). Colony PCR was used to identify plasmids with *EcoRV*-modified inserts. Those plasmids were subsequently sequenced to confirm *EcoR*V integration and determine details of sequence changes due to HDR. If the embryos were injected with the mloxP oligo, the genomic DNA was amplified using the same forward primer as listed above and a mloxP reverse primer, 5′-ATAAATTGCTATAATGTATGCTATACGAAGT-3′, or the same reverse primer as listed above and a mloxP forward primer, 5′-ACTTCGTATAGCATACATTATAGCAATTTAT-3′. For sequence analysis, the complete amplicon was produced using the gene-specific primers listed above and cloned (TOPO® TA Cloning^®^ Kit, Invitrogen). Colony PCR was used to find mloxP-positive plasmids. The positive plasmids were sequenced for confirmation of mloxP integration.

Injected fish from the same batch of somatically screened embryos were raised. When the fish were at least two months old, fin tissue was obtained using standard protocols pre-approved by Institutional Animal Care and Use Committee guidelines. The fish were anesthetized using Tricaine (approximately 200 μg/ml). The tail fins were trimmed with a fresh razor blade for each fish to prevent contamination. The most caudal 2--3mm of fin was biopsied and placed on ice until all fin biopsies were collected. 150 μl of 50mM NaOH was added to the fin clips prior to DNA isolation (above). Those fish that maintained somatic modifications were outcrossed to wild type fish and the embryos were screened for germline mutations. Somatic mutations were determined by RFLP analysis for EcoRV integration into *ponzr1*. Quantitative PCR of mloxP integrations into the *crhr2* locus were compared to a reference gene, RPS6Kb1. Twenty of 53 fish included \>0.2% of their DNA containing mloxP integrations into *crhr2* (CT of ≤10) and were prioritized for screening. For mloxP integration into *crhr2*, 42 fish that were not screened by quantitative PCR were also tested for germline transmission and no appreciable difference in germline transmission between these two methods was noted.

The PCR product for germline HDR events were cloned and sequenced. In one clone that contained a sequence insertion along with integration of the *EcoRV* site, the sequencing was more difficult presumably because the insertion tended to form a hairpin and disrupted the sequencing reaction. To obtain the full sequence, the PCR product was digested with *EcoRV* and each half sequenced separately. Similar cloning difficulties were observed in some *crhr2* lineages, but not for precise HDR or limited sequence addition.

The sequence addition process using ssDNA oligos is inherently less efficient than the relatively simpler NHEJ events seen in the GoldyTALEN-alone injected embryos. Therefore, to identify a precise HDR event, more fish will need to be raised and screened. Fin clipping the fish for maintenance of the somatic insertion may be a good indicator of germline transmission. Continued investigation into the mechanism of HDR incorporation in zebrafish will likely increase the efficiency of this technique.

Zebrafish Work {#S9}
--------------

The zebrafish work was conducted under full animal care and use guidelines with prior approval by the local institutional animal care committee's approval. *Danio rerio* transgenic lines were described previously: Tg(*fli1:efgp*)^y1^ vasculature^[@R19]^ and Tg(*gata1:dsred*)^sd2^ red blood cells^[@R20]^.

Data Analysis and Statistics {#S10}
----------------------------

ImageJ was used to quantify the percent GoldyTALEN-modified chromosomes by measuring the intensity of bands post-digestion. For each gel, the background was subtracted and each lane isolated to generate individual intensity plot profiles. A straight line was drawn across the bottom of each plot to eliminate inconsistencies caused by baseline skew. The intensity measurement for each band was added together to determine total intensity. To calculate percent cutting, the intensity of the top band was divided by the total intensity. A student's T-test was used to compare TALEN scaffold cutting efficiencies. To measure the differences between pTAL and GoldyTALEN at two different loci, several whisker plots were constructed ([Figure 1C](#F1){ref-type="fig"}). The interquartile range (IQR; Q3-Q1) is shown as a box, with the median value (Q2) being the horizontal line within the box. The upper and lower whiskers are the highest and lowest data point within 1.5 times the IQR added or subtracted from Q3 or Q1, respectively.

A similar approach was used to calculate the percent of HDR-converted chromosomes. The intensity of the digested products were added together and divided by the total intensity. The percent of embryos with an HDR signal was determined by dividing the number of embryos with signal by the total number of screened embryos.

Cell-free TALEN Restriction Endonuclease Assay {#S11}
----------------------------------------------

*In vitro* translation of 2 μg of each TALEN mRNA was conducted using the TNT^®^ Quick Coupled Transcription and Translation System (Promega). 5 μg of the *ponzr1* PCR product was included in the assay mix during *in vitro* translation of different TALEN combinations, allowing the translation and *in vitro* nuclease digestion to occur simultaneously. The highest signal was obtained when translation and digestion steps were conducted simultaneously presumably because the TALEN protein is unstable using these *in vitro* conditions. Translation was conducted for 2 hours at 30°C. To further facilitate TALEN *in vitro* nuclease activity, the assay mix was diluted five fold in *in vitro* digestion buffer (20mM Tris-HCl pH 7.5, 5mM MgCl2, 50 mM KCl, 5% Glycerol, and 0.5mg/ml BSA)^[@R27]^. The assay mix was incubated at 30°C for 4 hours. The digested DNA was purified using the PCR Purification kit (Qiagen), concentrated via ethanol precipitation, and run on a 2% agarose gel. No TALEN mRNA was added to the negative control.
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======================
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**a**, A schematic showing the layout of TALEN target sites. TALENs were targeted to flanking sequences surrounding a restriction enzyme site for easy screening through introduction of a restriction fragment length polymorphism. **b**, Relative activity of the GoldyTALEN and pTAL scaffolds at two loci, *ponzr1* and *crhr1.* Under each lane is the percent uncut DNA of a single larva, illustrating the increased activity of GoldyTALEN. **c**, Whisker plots of the percent uncut DNA demonstrates TALEN cutting efficiency at two loci. *ponzr1* TALENs demonstrate a significant (p \< 10^−16^), 6-fold increase in activity using GoldyTALEN. *crhr1* TALENs also demonstrate a significant (p \< 10^−9^), 15-fold increase in activity. n = number of embryos screened, mdn = the median percent cut. **d**, The *ponzr1* GoldyTALENs were more active in a cell-free restriction enzyme digestion assay. *ponzr1* DNA is labeled in both uncut and cut forms. − ctrl = negative control.](nihms405887f1){#F1}

![Increased TALEN efficiency results in biallelic gene targeting\
**a**, GoldyTALENs were designed against the *moesina*, *ppp1cab* and *cdh5* genes. All three gene targets contained a restriction enzyme site within the spacer region between the TALEN binding sites. Injection of GoldyTALEN mRNAs demonstrated a nearly complete loss of the restriction enzyme site in the amplicons of somatic tissue. Each lane is the amplification product from a group of 10 embryos. Mutant seq (%) = percentage of amplicons that carry mutant sequences as determined by sequencing 10 clones ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). **b--d**, Injection of *cdh5* GoldyTALENs (**d**) phenocopies the MO-based loss-of-function phenotype (**c**). Brightfield images (top panels) show pronounced cardiac edema (arrows) in both GoldyTALEN (**d**)- and MO (**c**)-injected larvae at 2 days post fertilization. Using the Tg(*fli1*-*egfp*)*^y1^* line, the intersomitic vessels were visualized (bottom panels) and show a loss of lumen formation (white arrow) in both the MO (**c**)- and GoldyTALEN (**d**)-injected larvae. The Tg(*gata1:dsred*)^sd2^ line revealed reduced circulation in GoldyTALEN- and MO-injected larvae, demonstrated by the increase in red fluorescence in the confocal images (see Movies 1--3).](nihms405887f2){#F2}

![Targeted genome editing using GoldyTALENs\
**a**, A schematic of the *ponzr1* locus with the ssDNA sequence used to introduce a targeted exogenous *EcoRV* sequence into the genome *in vivo*. The left and right TALEN binding sites are shown in red and orange, respectively, and the spacer region is in blue. **b**, A representative gel demonstrating germline transmission of the HDR-based *EcoRV* sequence in 3 out of 4 fin tissue-positive fish. **c**, Sequence analysis of the three germline-transmitting lines. The first fish transmitting HDR-based genome changes through the germline (\#1) yielded 7 out of 96 embryos with an incorporated *EcoRV* site. The genomes of all 7 embryos showed the same modified sequence. The second founder fish (\#2) yielded 7 out of 46 embryos with *EcoRV* incorporation. All 7 embryos showed precise HDR-based addition of the *EcoRV* sequence. The third fish with germline transmission (\#3) yielded 5 out of 18 embryos with an incorporated *EcoRV* site, and showed a mosaic germline as demonstrated by offspring with three different modified sequences. One embryo included precise HDR-based *EcoRV* addition. The other 4 embryos contained sequence insertions on the 5′ end with two embryos each harboring the specific sequences changes.](nihms405887f3){#F3}

![Germline mloxP integration into the *crhr2* locus\
**a**, A diagram of the TALEN target sites with the mloxP ssDNA oligo. The left and right TALEN target sequences are red and orange, respectively, the spacer region is blue, and the oligo's right homology arm is in purple. The mloxP sequence is underlined. **b,** Germline screening of the *crhr2* locus. 53 adult fish were prescreened via fin biopsy. Of those prescreened, 20 demonstrated mloxP maintenance. 16 F0s were outcrossed with 2 showing germline transmission. 42 unscreened F0s were outcrossed and 4 demonstrated germline transmission. **c,** Sequence confirmation of three mloxP germline fish. One fish demonstrated precise germline HDR while two showed indels. In \#NS24, we saw the reverse complement of the mloxP was noted (shaded in grey).](nihms405887f4){#F4}

![*in vivo* TALEN-induced genome editing outcomes\
TALENs efficiently create double-stranded breaks in chromosomal DNA and catalyze three major outcome classes. First, error-prone NHEJ produces an indel in and near the spacer region of the TALEN binding site. If a complementary ssDNA oligonucleotide is also added, two different outcomes are noted. First, HDR precisely uses the exogenous sequence information in the ssDNA to add sequence at the cut site. Alternatively, ssDNA acts as a primer for 3′ integration of the oligonucleotide but the 5′ end undergoes error-prone NHEJ^[@R22]^.](nihms405887f5){#F5}
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